Targeting schwann cell-immune interactions in neurofibromatosis type 1

The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $858,033 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, titled "TARGETING SCHWANN CELL-IMMUNE INTERACTIONS IN NEUROFIBROMATOSIS TYPE 1", will fund research focused on improving treatment approaches for neurofibromatosis type 1, a genetic disorder that causes tumor growth in the nervous system. The grant award period runs from August 1, 2024 to July 31, 2027.

The Children's Hospital Medical Center has been further awarded a $858,033 sub-grant to The Geneva Foundation, a non-profit research organization, to conduct research on "TARGETING SCHWANN CELL - MACROPHAGE INTERACTIONS IN NEUROFIBROMATOSIS TYPE 1". This sub-award, made under the primary Project Grant, will support collaborative work between the two organizations to investigate Schwann cell-macrophage interactions and develop potential new treatment approaches for neurofibromatosis type 1.